Format

Send to

Choose Destination
J Med Imaging (Bellingham). 2018 Jan;5(1):011014. doi: 10.1117/1.JMI.5.1.011014. Epub 2017 Dec 23.

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.

Author information

1
University of California San Francisco, Department of Biostatistics and Epidemiology, San Francisco, California, United States.
2
University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States.
3
University of California San Francisco, Department of Laboratory Medicine, San Francisco, California, United States.
4
University of California San Francisco, Department of Radiology and Biomedical Imaging, San Francisco, California, United States.
5
University of California San Francisco, Department of Surgery, San Francisco, California, United States.
6
George Mason University, Center for Applied Proteomics and Molecular Medicine, Manassas, Virginia, United States.
7
University of California San Francisco, Department of Radiation Oncology, San Francisco, California, United States.

Abstract

Although the role of cancer-activated stroma in malignant progression has been well investigated, the influence of an activated stroma in therapy response is not well understood. Using retrospective pilot cohorts, we previously observed that MRI detected stromal contrast enhancement was associated with proximity to the tumor and was predictive for relapse-free survival in patients with breast cancer receiving neoadjuvant chemotherapy. Here, to evaluate the association of stromal contrast enhancement to therapy, we applied an advanced tissue mapping technique to evaluate stromal enhancement patterns within 71 patients enrolled in the I-SPY 1 neoadjuvant breast cancer trial. We correlated MR stromal measurements with stromal protein levels involved in tumor progression processes. We found that stromal percent enhancement values decrease with distance from the tumor edge with the estimated mean change ranging [Formula: see text] to [Formula: see text] ([Formula: see text]) for time points T2 through T4. While not statistically significant, we found a decreasing trend in global stromal signal enhancement ratio values with the use of chemotherapy. There were no statistically significant differences between MR enhancement measurements and stromal protein levels. Findings from this study indicate that stromal features characterized by MRI are impacted by chemotherapy and may have predictive value in a larger study.

KEYWORDS:

MRI; breast cancer; enhancement; neoadjuvant; stroma

Supplemental Content

Full text links

Icon for Society of Photo-Optical Instrumentation Engineers Icon for PubMed Central
Loading ...
Support Center